Expanded indication/New formulation - Takhzyro (lanadelumab)

Takhzyro (lanadelumab) - expanded indication for routine prophylaxis of hereditary angioedema in pediatric patients 2 years and older; now available in injection (pre-filled syringe) form in the following strengths: 150 mg per mL, 300 mg per 2 mL.